UY25904A1 - Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina - Google Patents

Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina

Info

Publication number
UY25904A1
UY25904A1 UY25904A UY25904A UY25904A1 UY 25904 A1 UY25904 A1 UY 25904A1 UY 25904 A UY25904 A UY 25904A UY 25904 A UY25904 A UY 25904A UY 25904 A1 UY25904 A1 UY 25904A1
Authority
UY
Uruguay
Prior art keywords
pyridin
methoxy
methyl
pyrimidin
phenoxy
Prior art date
Application number
UY25904A
Other languages
English (en)
Inventor
Volker Breu
Hans Peter Wessel
Philippe Coassolo
Rolf Huber
Werner Neidhart
Henri Ramuz
Sebastien Roux
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY25904A1 publication Critical patent/UY25904A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos de fórmula (I), sus sales estables y ésteres derivados farmacéuticamente aceptables, así como procedimientos para su preparación, donde: R1 es piridilo, pirrolilo, imidazolilo, tiazolilo, tiazolinilo u oxazolilo, sustiuidos opcionalmente con halógeno, alquilo inferior, hidroxi-alquilo-inferior o alquenilo inferior; R2 es R21 ( siendo R1: ciano, hidroxi-alquilo-inferior, carboxi, entre otros) , -O-R22-, -N-R22 ( siendo R22: hidrógeno, alcanoilo inferior, carboxialquilo inferior, alcoxicarbonilo inferior, entre otros) o heterociclilo, el cual puede estar opcionalmente mono-, di- o tri-sustituido independientemente; X es -CH- o -N-. Ejemplos de compuesto seleccionados de fórmula (I): Ácido 4-[4-metoxi-5-(2-metoxi-fenoxi)-6-(5-metil-piridin-2-sulfonilamino)-pirimidin-2-il]-piridin-2-carboxílico; Éster metílico del ácido 4-[4-metoxi-5-(2-metoxi-fenoxi)-6-(5-metil-piridin-2-sulfonilamino)-pirimidin-2-il]-piridin-2-carboxílico; Ácido 5-metil-piridin-2-sulfónico [2-(2-hidroximetil-piridin-4-il)-6-metoxi-5-(2-metoxi-fenoxi)-pirimidin-4-il]-amida; entre otros. Estos compuestos son inhibidores de receptores de endotelina y pueden por lo tanto, usarse para el tratamiento de trastornos que están asociados con el tono vascular anormal y la disfunción endotelial. VER REIVINDICACIONES
UY25904A 1999-01-18 2000-01-14 Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina UY25904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99100784 1999-01-18

Publications (1)

Publication Number Publication Date
UY25904A1 true UY25904A1 (es) 2001-07-31

Family

ID=8237359

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25904A UY25904A1 (es) 1999-01-18 2000-01-14 Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina

Country Status (31)

Country Link
US (1) US6242601B1 (es)
EP (1) EP1149091B1 (es)
JP (1) JP3983477B2 (es)
KR (1) KR100478797B1 (es)
CN (1) CN1340049A (es)
AR (1) AR029879A1 (es)
AT (1) ATE389648T1 (es)
AU (1) AU763112B2 (es)
BR (1) BR0007595A (es)
CA (1) CA2359363C (es)
CO (1) CO5150187A1 (es)
CZ (1) CZ20012546A3 (es)
DE (1) DE60038365D1 (es)
ES (1) ES2301476T3 (es)
GC (1) GC0000248A (es)
HR (1) HRP20010515A2 (es)
HU (1) HUP0200021A3 (es)
IL (2) IL144055A0 (es)
MA (1) MA27124A1 (es)
MY (1) MY121136A (es)
NO (1) NO322800B1 (es)
NZ (1) NZ512662A (es)
PE (1) PE20001421A1 (es)
PL (1) PL350093A1 (es)
RU (1) RU2224757C2 (es)
TR (1) TR200102071T2 (es)
TW (1) TWI284642B (es)
UY (1) UY25904A1 (es)
WO (1) WO2000042035A1 (es)
YU (1) YU50001A (es)
ZA (1) ZA200105279B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ME00275B (me) * 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
NZ525614A (en) * 2000-12-18 2005-03-24 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ES2275931T5 (es) * 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
WO2003068229A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003068746A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
EP1569914B1 (en) * 2002-12-02 2009-02-18 Actelion Pharmaceuticals Ltd. Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US7269460B2 (en) * 2003-02-28 2007-09-11 Medtronic, Inc. Method and apparatus for evaluating and optimizing ventricular synchronization
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
KR20080111137A (ko) * 2006-04-13 2008-12-22 액테리온 파마슈티칼 리미티드 초기 단계 특발성 폐 섬유증을 위한 엔도텔린 수용체 대항제
EP2021324B1 (en) 2006-05-29 2011-12-14 NicOx S.A. Nitrated heterocyclic compounds as endothelin receptor antagonist
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
CN107108550B (zh) * 2014-11-21 2020-03-03 大金工业株式会社 新型的氟代不饱和环状碳酸酯及其制造方法
CN109260164A (zh) * 2018-10-07 2019-01-25 威海贯标信息科技有限公司 一种阿伏生坦片剂组合物
CN112898208B (zh) * 2021-01-29 2023-06-20 中国医科大学 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用
CN112778215B (zh) * 2021-01-29 2023-06-20 中国医科大学 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用
EP4448511A1 (en) 2021-12-17 2024-10-23 Idorsia Pharmaceuticals Ltd Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
WO1996016963A1 (de) * 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
TW313568B (es) * 1994-12-20 1997-08-21 Hoffmann La Roche
EP0882719B1 (en) * 1995-12-20 2001-05-16 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same

Also Published As

Publication number Publication date
HUP0200021A2 (hu) 2002-05-29
ES2301476T3 (es) 2008-07-01
YU50001A (sh) 2004-03-12
IL144055A0 (en) 2002-04-21
WO2000042035A1 (en) 2000-07-20
GC0000248A (en) 2006-11-01
PE20001421A1 (es) 2000-12-18
MY121136A (en) 2005-12-30
ZA200105279B (en) 2002-10-07
IL144055A (en) 2007-07-24
KR100478797B1 (ko) 2005-03-24
CN1340049A (zh) 2002-03-13
NZ512662A (en) 2003-11-28
US6242601B1 (en) 2001-06-05
NO20013454D0 (no) 2001-07-12
ATE389648T1 (de) 2008-04-15
JP3983477B2 (ja) 2007-09-26
AU2663000A (en) 2000-08-01
MA27124A1 (fr) 2005-01-03
HRP20010515A2 (en) 2003-06-30
CO5150187A1 (es) 2002-04-29
BR0007595A (pt) 2001-10-16
AR029879A1 (es) 2003-07-23
CZ20012546A3 (cs) 2001-12-12
CA2359363C (en) 2006-03-14
TWI284642B (en) 2007-08-01
NO322800B1 (no) 2006-12-11
EP1149091B1 (en) 2008-03-19
DE60038365D1 (en) 2008-04-30
PL350093A1 (en) 2002-11-04
HUP0200021A3 (en) 2003-01-28
AU763112B2 (en) 2003-07-10
RU2224757C2 (ru) 2004-02-27
KR20010094746A (ko) 2001-11-01
CA2359363A1 (en) 2000-07-20
JP2002534518A (ja) 2002-10-15
NO20013454L (no) 2001-07-12
EP1149091A1 (en) 2001-10-31
TR200102071T2 (tr) 2002-03-21

Similar Documents

Publication Publication Date Title
UY25904A1 (es) Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina
AR112118A2 (es) Inhibidores de pi-3 quinasa
AR050953A1 (es) Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales
AR059249A1 (es) Compuesto amina trisustituido
PE20140858A1 (es) Derivados de piperidina como inhibidores de renina
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
AR059248A1 (es) Heterociclos nitrogenados y sus usos como inhibidores de aterosclerosis. composiciones farmaceuticas
CR9690A (es) 3-acilaminobenzanilidas insecticidas
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR058719A1 (es) Derivados de isoxazol-4-il-oxadiazol
PE20060481A1 (es) N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas
ES2561425T3 (es) (Aza)ciclohexanos carbonilados como ligandos de receptor D3 de la dopamina
PE20061158A1 (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa y su preparacion
PE20081454A1 (es) Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
PE20070407A1 (es) Compuestos derivados de pirazina como antagonistas del receptor a2b de adenosina
PE20040450A1 (es) Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
AR071323A1 (es) Derivados heterociclicos de piridazinonas activadores de glucoquinasas, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de la diabetes mellitus tipo ii.
PE20091732A1 (es) Dihidropirazolonas sustituidas y su uso
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20081222